|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia.
|
31688198 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in hematological malignancies.
|
30320942 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FLT3 is frequently mutated and overexpressed in acute myelogenous leukemia (AML) and other hematologic malignancies.
|
28107692 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy with a grave prognosis.
|
26438511 |
2015 |
|
Hematologic Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, the role in leukemogenesis of wild-type (wt) FLT3, which is highly expressed in many hematologic malignancies, is unclear.
|
24269847 |
2014 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT).
|
23497317 |
2013 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Acute myeloid leukemia with a FLT3 internal tandem duplication (FLT3/ITD) mutation is an aggressive hematologic malignancy with a generally poor prognosis.
|
21586749 |
2011 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among them, constitutively activating mutations of the receptor tyrosine kinases (RTKs), such as c-Kit, platelet-derived growth factor receptor (PDGFR) and FLT3, are often involved in the pathogenesis of various types of hematologic malignancies.
|
18177485 |
2008 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The FMS-like tyrosine kinase 3 (FLT3) gene, belonging to the receptor tyrosine kinase (TK) subclass III family, plays an important role in normal hematopoiesis and is one of the most frequently mutated genes in hematologic malignancies as well as an attractive target for directed inhibition.
|
16761019 |
2006 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FLT3 in human hematologic malignancies.
|
12400596 |
2002 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematologic malignancies.
|
11290608 |
2001 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematologic malignancies.
|
11290608 |
2001 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.
|
9324277 |
1997 |